Britain Launches Weight-Loss Injection Trial for Unemployed Obese Individuals
The British government is set to trial the use of weight-loss injections as part of a new initiative aimed at helping unemployed individuals struggling with obesity. Health Minister Wes Streeting announced the program, stating that obesity is a significant issue affecting millions in the UK, leading to increased sick days and placing a heavy financial burden on the National Health Service (NHS). The rising obesity rates, which have climbed from 22.6% in 2015-2016 to 26.2% in 2023, are costing the NHS approximately £11 billion ($14.37 billion) annually, surpassing the costs associated with smoking.
The initiative, supported by a £279 million ($365 million) investment from US pharmaceutical giant Eli Lilly, will involve a five-year trial of the Mounjaro weight-loss injection. This trial will target up to 3,000 patients, specifically focusing on those who are both obese and unemployed. Recent studies have shown that Mounjaro is more effective for weight loss compared to other medications like Ozempic and Wegovy, which are produced by Novo Nordisk.
Broader Health Initiatives and Economic Implications
In addition to the weight-loss injection trial, the Labour government has introduced several measures to combat unhealthy lifestyles, including a ban on junk food advertising aimed at children. Prime Minister Keir Starmer emphasized the economic importance of these weight-loss drugs, asserting that they are essential for helping individuals return to work and alleviating pressure on the NHS. The public health advisory body has recommended a phased rollout of the Mounjaro program, aiming to provide access to the injections for 250,000 people within three years.
